Radiotherapy and immune checkpoint blockades: a snapshot in 2016
Radiation Oncology Journal
;
: 250-259, 2016.
Artigo
em Inglês
| WPRIM
| ID: wpr-33377
ABSTRACT
Immune checkpoint blockades including monoclonal antibodies (mAbs) of cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed death-1 (PD-1), and programmed death-ligand 1 (PD-L1) have been emerged as a promising anticancer therapy. Several immune checkpoint blockades have been approved by US Food and Drug Administration (FDA), and have shown notable success in clinical trials for patients with advanced melanoma and non-small cell lung cancer. Radiotherapy is a promising combination partner of immune checkpoint blockades due to its potent pro-immune effect. This review will cover the current issue and the future perspectives for combined with radiotherapy and immune checkpoint blockades based upon the available preclinical and clinical data.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Radioterapia
/
United States Food and Drug Administration
/
Linfócitos T Citotóxicos
/
Carcinoma Pulmonar de Células não Pequenas
/
Receptor de Morte Celular Programada 1
/
Melanoma
/
Anticorpos Monoclonais
Limite:
Humanos
Idioma:
Inglês
Revista:
Radiation Oncology Journal
Ano de publicação:
2016
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS